News | December 21, 2008

Bard Receives FDA Clearance For E-Luminexx Vascular Stent

December 22, 2008 - C. R. Bard Inc. recently received FDA clearance to market the E-Luminexx Vascular Stent - a flexible, self-expanding nitinol stent.

The E-Luminexx is intended to treat patients with common or external iliac artery occlusive disease. Current estimates indicate each year more than 140,000 patients are candidates for iliac stent procedures in the U.S. This patient population is expected to grow by more than 10 percent annually due to the increased clinician focus on treating peripheral arterial disease and the growing number of diabetic patients who are at higher risk of developing these occlusions.

Bard’s prospective, multi-center, non-randomized, clinical study of 134 patients measuring the E-Luminexx Vascular Stent against objective performance criteria demonstrated a nine-month primary patency of 94 percent and a site reported anatomic success rate (

For more information: www.crbard.com

Related Content

Intact Vascular Announces $20 Million Series C Financing
News | Stents Peripheral | April 27, 2018
April 27, 2018 — Intact Vascular Inc. recently closed a Series C financing totaling $20 million.
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral | July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral | July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral | April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral | March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
TOBA II BTK clinical trial, Intact Vascular, Tack Endovascular System, CLI, critical limb ischemia, first patient treated
News | Stents Peripheral | March 02, 2017
Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
Biotronik, Pulsar-18 bare metal self-expanding stent, BMS SE, BIOFLEX PEACE trial, 12-month results, VEITHsymposium 2016
News | Stents Peripheral | December 13, 2016
Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal self-expanding stent (...
LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral | December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
Gore, Tigris stent, fluoropolymer nitinol stent, peripheral artery disease

The Gore Tigris is a dual-component stent with a unique fluoropolymer / nitinol design.

Technology | Stents Peripheral | August 02, 2016
August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L.
Technology | Stents Peripheral | April 27, 2016
Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering...
Overlay Init